Latest news for Swire Properties (OTC:SWPFF) Stock

Swire Properties is a Hong Kong-based property investor, and Hong Kong's largest office landlord. Its Hong Kong portfolio provides more than 13 million square feet of gross floor area, with its portfolio of Grade A office contributing over 9 million square feet. The firm also holds investment properties and development projects in China, the United States and Southeast Asia. Rental income accounts for over 60% of its total revenue, with property development and hotel operations contributing the balance. The company was listed in 2012. Parent company Swire Pacific holds an 82% stake.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AAWW

ABMD

ACAN

ACRGF

ADAP

ADPT

ADRO

AIHS

AKCA

ALBO

ALKS

ALNA

AMTD

ANDE

ANGI

ANGO

AOBC

ARHVF

ASMB

ASRT

ASTC

Adtalem Global Education Inc. Common Stock

ATGE

AUPH

AUSAF

AVGR

AWLCF

AWSM

AXGN

BABYF

BCOR

BEAT

BERY

BGFT

BICX

BKCC

BLUE

BMRN

BNFT

BOCH

BOMN

BORR

BOSSY

BREW

BTHCF

BTKRF

BYZN

CADMF

CBDS

CBIIF

CCHWF

CDBMF

CDTI

CEIX

CHNC

CHOOF

CHRA

CHWY

CLVS

CLXT

CNNXF

CNONF

CRBP

CRVS

CSLT

CSTL

CTMX

CTRA

CTST

CVVUF

CWBR

CXXIF

CYTR

DFFN

DIIBF

DLPH

DNOW

DRIO

DTIL

DXBRF

EEVVF

EGRNF

ELGX

ELOX

EMERALD HEALTH THERAPUTCS by Emerald Health Therapeutics Inc.

EMHTF

ENBL

Stocks That Hit 52-Week Lows On Wednesday

SWIRE PROPERTIES LTD ORD by Swire Properties Ltd.

Swire Properties Ltd

Aegis Capital analyst Rommel Dionisio initiates coverage on Flora Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) with a Buy rating and announces Price Target of $4.

Price Target

Initiation

Analyst Ratings

FLGC

Aegis Capital Initiates Coverage On Flora Growth with Buy Rating, Announces Price Target of $4

Amid&nbsp;Donald Trump&#8216;s recent pledge to boost U.S. oil production significantly, questions arise about the necessity and impact of such a move.&nbsp;Vikas Dwivedi, a global energy strategist at&nbsp;Macquarie Group, has expressed skepticism regarding the need for an additional 3 million barrels per day.
What Happened: Dwivedi discussed the potential impact of Trump&#8217;s second term on the U.S. oil supply. Talking to&nbsp;<a href="https://www.cnbc.com/video/2024/11/25/us-oil-supply-increases-will-be-marginal-with-trump-2point0-macquarie.html">CNBC</a> &#8220;Squawk Box&#8221;&nbsp;on Monday, he said that anticipates only marginal increases in supply, despite Trump&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42130859/as-trump-backs-drill-baby-drill-his-doge-co-lead-elon-musk-believes-all-energy-generation-will-be-solar-heres-what-ubs-recommends-after-election-dip">&#8220;Drill Baby Drill&#8221; stance.</a>
&#8220;We actually think there will be marginal supply increases from the U.S. The risks to supply will eventually be marginal but in the beginning of the administration, we think, the moves that they will make will increase supply risks,&#8221; Dwivedi said, adding the risks arising particularly through attempts to limit Iranian oil exports. He noted that the Ships Act aims to eliminate entities facilitating Iranian crude sales, but this could inadvertently reduce global oil supply.
Addressing Trump&#8217;s ambitious energy policy, Dwivedi questioned the necessity of increasing U.S. oil production.
&#8220;The real challenge is: does the world need that much oil? And if the U.S. did grow 3 million barrels a day during the Trump Administration, that&#8217;s like 750,000 a day over four years,&#8221; he explained
&#8220;I think the right question to ask energy executives is are you okay with $40 oil because I think that&#8217;s what you would end up with and are you okay with trying to figure out how to maintain production and um you know still be able to do the dividends and the share buybacks that are now not as discretionary as they used to be.&#8221;
Furthermore, Dwivedi highlighted the geopolitical risks associated with a rapid U.S. withdrawal of support for Ukraine. He warned that if Ukraine feels cornered, it might target Russian oil infrastructure, which could further impact the global oil supply.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/24/11/42153356/is-warren-buffett-preparing-for-a-market-downturn-with-berkshire-hathaways-325b-cash-pile-analyst-says-internet-bubble-and-2008-crash-may-have-lessons?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Is Warren Buffett Preparing For A Market Downturn With Berkshire Hathaway&#8217;s $325B Cash Pile? Analyst Says</a>
Why It Matters: Trump&#8217;s energy strategy, which includes faster permitting and weaker environmental regulations, aims to cut American energy costs significantly. However, experts have warned that these<a href="https://www.benzinga.com/news/24/09/40703958/trumps-drill-baby-drill-pledge-may-not-deliver-promised-energy-price-cuts-experts-warn"> promises may not materialize</a> due to the complexities of global and regional energy markets. Many oil drillers remain cautious about increasing production, opting instead to return cash to shareholders. This hesitancy is compounded by factors like weather patterns and global conflicts, which are not easily influenced by policy changes.
Meanwhile, Elon Musk, who has been announced to head the new Department of Government Efficiency (DOGE), continues to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42130859/as-trump-backs-drill-baby-drill-his-doge-co-lead-elon-musk-believes-all-energy-generation-will-be-solar-heres-what-ubs-recommends-after-election-dip">advocate for solar power</a> as the future of energy generation, presenting a different vision from Trump&#8217;s fossil fuel-focused approach. Analysts also see an opportunity for investment in renewables, highlighting the sector&#8217;s potential for growth even amid political shifts.
Price Action: As per <a href="https://pro.benzinga.com">Benzinga Pro</a>, oil ETFs have seen slight gains in the past one month surrounding the presidential elections. As of Monday, ProShares Ultra Bloomberg Crude Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UCO#NYSE">UCO</a>) increased 3.51%, SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) increased by 10.78%, while MicroSectorsTM Oil &amp; Gas Exploration &amp; Production 3X Leveraged ETNs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OILU#NYSE">OILU</a>) increased by 20.99%.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42152947/satellite-images-reveal-north-korea-reportedly-receiving-illicit-oil-from-russia?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Satellite Images Reveal North Korea Reportedly Receiving Illicit Oil from Russia</a></li>
</ul>
Image via Shutterstock

Commodities

OILU

Amid Trump's 'Drill Baby, Drill' Pledge, Strategist Predicts US Oil Supply Will See 'Marginal' Increase: 'Does The World Need That Much Oil?'

D. Boral Capital analyst Jason Kolbert maintains Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) with a Buy and maintains $29 price target.

IMNN

D. Boral Capital Maintains Buy on Imunon, Maintains $29 Price Target

WIIM

AMPG

AmpliTech Group shares are trading lower after the company priced a $1.4 million registered direct offering at $0.92 per share.

Nano Nuclear Energy shares are trading lower after the company announced a $60 million private placement with three accredited institutional investors.

Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>).
GeminiBio has a 39-year history of supporting FBS customers. With this agreement, GeminiBio builds on these capabilities, by securing the manufacturing and global sales rights for Bio-Techne's R&amp;D Systems fetal bovine serum (FBS) product brands, Optima, Premium Select, and Premium. Following Bio-Techne's decision to discontinue their FBS products, GeminiBio worked closely with the company to create a seamless transition plan, ensuring continuous access to these high-quality FBS products for existing customers.

Asset Sales

TECH

Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum Product Rights And Inventory From Bio-Techne; No Financial Terms Disclosed

Biotech

LEXX

Lexaria Completes Dosing In Human Pilot Study #3 Investigating DehydraTECH-Processed Tirzepatide From Zepbound

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/62cd59300ee57b0001a11a55/robert-cox">Goldman Sachs analyst Robert Cox</a> downgraded Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) from Buy to Neutral and maintained the price target of $313. Arthur J. Gallagher shares closed at $304.29 on Friday. <a href="https://www.benzinga.com/quote/AJG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup analyst Keith Horowitz downgraded the rating for M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) from Buy to Neutral but raised the price target from $220 to $230. M&amp;T Bank shares closed at $221.12 on Friday. <a href="https://www.benzinga.com/quote/MTB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group analyst Joseph Feldman downgraded Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) from Outperform to Market Perform and lowered the price target from $102 to $95. Five Below shares closed at $86.92 on Friday. <a href="https://www.benzinga.com/quote/FIVE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo analyst Stephen Baxter downgraded the rating for HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Equal-Weight to Underweight and slashed the price target from $400 to $320. HCA Healthcare shares closed at $324.93 on Friday. <a href="https://www.benzinga.com/quote/HCA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Tina Hou downgraded NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from Neutral to Sell and lowered the price target from $4.8 to $3.9. Nio shares closed at $4.84 on Friday. <a href="https://www.benzinga.com/quote/NIO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NIO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1010" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25090521/image-269.png" alt="" class="wp-image-663428" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25090521/image-269.png 1010w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25090521/image-269-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25090521/image-269-768x457.png 768w" sizes="(max-width: 1010px) 100vw, 1010px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Downgrades

Pre-Market Outlook

FIVE

This Nio Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

KODK

Kodak Retirement Income Plan Trust Sells $764.4M In Illiquid Assets To Mastercard Foundation For $550.6M Cash, Signs Additional Agreements For $87.3M Sale To Other Investors, Retaining $161.3M In Illiquid Assets And $917.2M In Hedge Fund Assets Pending Redemption Proceeds

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $46 price target.

AVXL

D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

Loop Capital analyst Alan Gould maintains Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) with a Hold and lowers the price target from $38 to $35.

Loop Capital Maintains Hold on Warner Music Gr, Lowers Price Target to $35

Dear Damon shareholders, supporters, reservation holders and enthusiasts,
I am deeply grateful for your steadfast support and dedication over the past two and half years – a period that has proven challenging for us all. Your belief in our mission has been a cornerstone of our perseverance during a time when many early-stage startups struggled to survive. You deserve a transparent account of the journey we have endured together and an understanding of the hurdles that has led us to where we are now, starting with a roadmap of what we need to do to get to production.
Path To Production, Explained
Currently with 15 in-house engineers, we are leveraging a combination of our employees alongside key subcontractors and external experts to advance development. Late-stage engineering is mostly complete, with vehicle mechanics 90% finalized. Power electronics are also 90% complete, with ongoing validation and the integration of key features. Similarly, mechanical and cooling systems are 90% complete, while the battery system is 70% complete, with efforts focused on the development of the cell interconnect system.
With adequate funding, the project is expected to progress to the pre-production stage,&nbsp;starting with validation and design confirmation, where we'll aim to make a run of pre-production prototypes and test them against our design requirements and regulations to confirm the designs before we release to tooling. Ordering all the tools to make our first run of parts from will be the next big milestone, subject to our ability to raise sufficient capital to make this substantial investment. This pre-production phase has an estimated completion of late 2025. The Production &amp; Commercialization Stage is expected to occur in parallel, focusing on the establishment of the final assembly and test facility at our HQ in San Rafael, CA, along with the development of distribution and delivery infrastructure. This stage is expected to conclude in 2026 and pending additional capital to achieve, serial production can then begin.
Commercial production is expected to commence after passing various internal and external tests and undergoing a self-certification process required for US-bound vehicle homologation. These tests include: the completion of Damon's ride quality and long-term durability testing, completion of FCC Title 47 certification for the onboard charger, completion of UN 38.3 battery testing, completion of Damon's internal battery testing, extreme temperature operation verification, brake testing per FMVSS, and an internal and external review of FMVSS compliance with our engineering subcontractor.
What Led Us Here
In the spring of 2022, Damon successfully raised a US$26M Series B financing, which marked the beginning of our efforts to raise a Series C round with the assistance of two major banks. This funding was intended to kickstart production. However, following the volatile SPAC era, the financial landscape shifted dramatically. The bursting of this bubble led to a severe downturn in the markets, and our efforts to secure a Series C production financing were unsuccessful. Despite these circumstances, the company was able to bridge itself with the support of various investors - enough to cover essential costs, having significantly reduced expenses across the board.
Navigating Funding Challenges
Since early 2022, inflation rates grew to reach 40-year highs, the highest level since 1981. Simultaneously. interest rates reached 20-year highs, rocking the financial markets and virtually wiping out risk capital for private companies, especially for pre-revenue startups in the capital-intensive automotive sector. Because of this, pre-revenue electric vehicle company valuations fell by an average 85%, and very few survived. Damon is an anomaly that persevered, despite how little risk capital had been available to fund the company's path to production. As previously noted, the company had undertaken multiple cost-cutting measures across all areas to navigate through these challenging past two years. These necessary reductions have regrettably led to significant delays. The journey has been far from easy, but these tough decisions were essential to ensure our continued operation and future success.
Nevertheless, we&nbsp;have persevered - a testament to everyone's faith and resilience when compared to many high-tech automotive startups that did not survive. And now that we are on the Nasdaq, the dream of reinventing motorcycling is far from over.
Going Public&nbsp;
After all this, it became evident that transitioning to the public markets was the best viable route to secure the necessary funding for production. In October 2023, we signed a merger agreement with Grafiti Holdings. Why did we choose Grafiti? &nbsp;It was the best merger partner we identified, possessing the ability to provide us with bridge financing and additional funding sources to help fund our Nasdaq preparation efforts and the benefit of no debt or liabilities.
During the 13-months it took to complete the merger and secure our Nasdaq listing, we faced what oftentimes seemed like insurmountable challenges. These included maintaining essential operations, keeping the remaining staff onboard, and managing increasing costs associated with going public. Additionally, we had to navigate the arduous, tax, audit and public listing requirements of both Canada and the US. These demands impacted our ability to fund production preparations, which are costly, thus extending our timeline to production.
Fast forward to now, and we achieved the goal of getting listed on the Nasdaq. Now, as a public company, we hope to gain access to the additional capital we need to fund our path to production. And this is why we need your continuing faith, your support and your confidence in us. Because we still have a lot of work ahead of us.

Damon CEO Pens Letter Providing Business Update And Outlining Production Roadmap

On Friday, the FDA approved BridgeBio Pharma, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42150289/attruby-acoramidis-a-near-complete-ttr-stabilizer-90-approved-by-fda-to-reduce-cardiovascular-deat" rel="noreferrer noopener">cardiovascular-related hospitalization</a>.
The FDA approval is based on ATTRibute-CM Phase 3 study results, which showed that Attruby significantly reduced death and cardiovascular-related hospitalization and improved quality of life.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42072773/bridgebio-pharmas-acoramidis-shows-competitive-edge-against-pfizers-tafamidisa-in-lucrative-but-competitive-attr-cm-market" rel="noreferrer noopener">BridgeBio Pharma&#8217;s Acoramidis Shows Competitive Edge Against Pfizer&#8217;s Tafamidisa In Lucrative But Competitive ATTR-CM Market</a>
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR.
Attruby was designed to mimic a naturally occurring &#8220;rescue mutation&#8221; of the TTR gene (T119M) that targets the root cause of ATTR-CM, the destabilization of the native TTR tetramer.
Through near-complete TTR stabilization, Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes.
The ATTRibute-CM Phase 3 study enrolled 632 participants with symptomatic ATTR-CM associated with either wild-type or variant TTR.
BridgeBio submitted a Marketing Authorization Application to the European Medicines Agency, with a decision expected in 2025.
BridgeBio has granted&nbsp;Bayer AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BAYRY#OTC">BAYRY</a>)&nbsp;exclusive rights to commercialize acoramidis for ATTR-CM in Europe.
The company said it will provide Attruby for free to patients who participated in the trial.
William Blair writes, &#8220;We continue to view a reduction in all-cause mortality on label as a necessary distinction to gain major market share in ATTR-CM alongside Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) tafamidis.&#8221;
Since the Attruby label doesn&#8217;t include data on overall mortality, the William Blair analyst notes Pfizer might shift its marketing focus to emphasize claims about mortality benefits.
Price Action: BBIO stock is up 24.3% at $29.10 during the premarket session at last check Monday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/24/11/42162996/vertical-aerospace-soars-50-million-funding-boost-and-debt-conversion-propel-evtol-maker-forward" target="_blank" rel="noreferrer noopener">Vertical Aerospace Soars: $50 Million Funding Boost And Debt Conversion Propel eVTOL Maker Forward</a></li>
</ul>

Analyst Color

Equities

Health Care

BAYRY

BBIO

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

The virtual event will take place on Monday, December 2, 2024, at 4:30 PM ET
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.januxrx.com%2F&amp;esheet=54157214&amp;newsitemid=20241125381273&amp;lan=en-US&amp;anchor=Janux+Therapeutics%2C+Inc.&amp;index=1&amp;md5=e257bbb56600d7291454ec697d3b55f8">Janux Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced it will host a virtual event on Monday, December 2, 2024, at 4:30 PM ET.
David Campbell, Ph.D., President &amp; Chief Executive Officer, will provide an update on JANX007 Phase 1a dose escalation data and doses selected for Phase 1b expansion studies in adult subjects with metastatic castration-resistant prostate cancer (mCRPC).

JANX

Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In mCRPC And Doses Selected For Phase 1b Expansion Studies

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Office Properties Income Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPI#NASDAQ">OPI</a>)</h3>
<ul>
<li>On Oct. 30, Office Properties IT reported worse-than-expected third-quarter FFO results. The company's stock fell around 40% over the past month and has a <a href="https://www.benzinga.com/quote/OPI">52-week low of $1.06</a>.</li>
<li>RSI Value: 20.67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>OPI Price Action: Shares of Office Properties Income Trust closed at $1.14 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">latest OPI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="911" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041017/image-261.png" alt="" class="wp-image-662916" style="width:644px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041017/image-261.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041017/image-261-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041017/image-261-768x701.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">Wheeler Real Estate Investment Trust Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)</h3>
<ul>
<li>On Nov. 15, Wheeler Real Estate Investment Trust announced a 1-for-2 reverse stock split effective Nov. 18. The company's stock fell around 32% over the past five days and <a href="https://www.benzinga.com/quote/WHLR">has a 52-week low</a> of $5.79.</li>
<li>RSI Value: 26.03</li>
<li>WHLR Price Action: Shares of Wheeler Real Estate Investment Trust fell 2.2% to close at $8.50 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">trend in WHLR stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041125/image-262.png" alt="" class="wp-image-662917" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041125/image-262.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041125/image-262-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041125/image-262-768x712.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Creative Media &amp; Community Trust Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>)</h3>
<ul>
<li>On Nov. 8, Creative Media reported a quarterly loss of $1.22 per share which missed the analyst consensus estimate of a loss of 64 cents per share. &#8220;We continue to make progress on our previously announced actions to accelerate our focus towards premier multifamily assets, strengthen our balance sheet and improve our liquidity,&#8221; said David Thompson, Chief Executive Officer of Creative Media &amp; Community Trust Corporation. The company's stock fell around 25% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/CMCT">low of $0.21.</a></li>
<li>RSI Value: 21.55</li>
<li>CMCT Price Action: Shares of Creative Media &amp; Community Trust fell 9.1% to close at $0.22 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">breakout in CMCT shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041229/image-263.png" alt="" class="wp-image-662923" style="width:714px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041229/image-263.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041229/image-263-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041229/image-263-768x717.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Long Ideas

CMCT

WHLR

Top 3 Real Estate Stocks That May Explode In Q4

icometrix' FDA-cleared quantitative brain solution for neurological conditions including Alzheimer's and multiple sclerosis is seamlessly integrated into Philips next generation BlueSeal MR scanners, and will be deployed in its comprehensive informatics platform &nbsp;

Events

Philips And Icometrix Report Results Of MRI Brain Scans To Optimize Alzheimer And Multiple Sclerosis Diagnosis At RSNA 2024

Telsey Advisory Group analyst Dana Telsey maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Outperform and maintains $42 price target.

BBWI

Telsey Advisory Group Maintains Outperform on Bath & Body Works, Maintains $42 Price Target

Partnership enhances gift card shopping experience with quick local deliveries from DashMart and other popular merchants within the DoorDash app
ATLANTA, Nov. 25, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4310547-1&amp;h=4183263924&amp;u=https%3A%2F%2Fwww.incomm.com%2F&amp;a=InComm+Payments">InComm Payments</a>, a global payments technology company, and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4310547-1&amp;h=4056120216&amp;u=https%3A%2F%2Fwww.doordash.com%2F&amp;a=DoorDash">DoorDash</a>, the premier local commerce platform, today announced a partnership enabling consumers to browse, purchase and order delivery of gift cards for hundreds of merchants within the DoorDash app. The offering will launch on Friday, Nov. 29, with promotions beginning on Black Friday that offer&nbsp;limited-time discounts on select digital gift card orders made through the app or website&#x2A; by eligible customers.

DASH

DoorDash Selects InComm Payments As Partner To Launch In-App Gift Card Shopping Experience

Loop Capital analyst Jeffrey Stevenson maintains GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) with a Hold and raises the price target from $85 to $93.

Loop Capital Maintains Hold on GMS, Raises Price Target to $93

Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Nutanix to report an earnings per share (EPS) of $0.30.
The announcement from Nutanix is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.07, leading to a 20.31% increase in the share price on the subsequent day.
Here's a look at Nutanix's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.16</td>
<td>0.29</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.27</td>
<td>0.28</td>
<td>0.46</td>
<td>0.29</td>
</tr>
<tr>
<td>Price Change %</td>
<td>20.0%</td>
<td>-23.0%</td>
<td>7.000000000000001%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732543326_0.png" alt="eps graph" />
<h3>Performance of Nutanix Shares</h3>
Shares of Nutanix were trading at $73.18 as of November 22. Over the last 52-week period, shares are up 80.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NTNX/earnings">To track all earnings releases for Nutanix visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

NTNX

What to Expect from Nutanix's Earnings

CK Asset Holdings: It's Not About Hong Kong Anymore, Management's Focus Seems To Have Shifted

Swire Properties: Buyback Plan Draws Attention To Stock's Undervaluation (Rating Upgrade)

Comments

Swire Properties

News

Latest news for Swire Properties (OTC:SWPFF) Stock

Wednesday, October 02, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga